GlassScriptPhysician profile
Steven Rosenberg
NPI 1245225630
$8,486.88
in general payments reported to CMS, 2019-2025
36 companies · $982 in 2025
The $982 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $582 · 2021: $1,330 · 2022: $1,510 · 2023: $1,306 · 2024: $1,105 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.66 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,466.15 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,300.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,128.90 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $811.52 | 2019-2025 | Dupixent |
| Genzyme Corporation | $582.27 | 2019-2025 | |
| Optinose US, INC. | $575.17 | 2019-2025 | |
| Pfizer INC. | $386.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.75 | 2021-2025 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $265.53 | 2019-2023 | Airduo Digihaler |
| Genentech USA, INC. | $258.85 | 2019-2023 | Xolair |
| Sun Pharmaceutical Industries INC. | $239.20 | 2024-2025 | |
| Amgen INC. | $116.96 | 2021-2023 | Tezspire |
| Grifols USA, LLC | $102.50 | 2021-2025 | Xembify |
| Aimmune Therapeutics, INC. | $97.18 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $94.18 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $88.11 | 2023-2025 | Ruconest |
| Abbvie INC. | $81.99 | 2021-2022 | |
| Kaleo, INC. | $60.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.96 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $50.18 | 2023-2024 | Ryaltris |
| Covis Pharma Gmbh | $44.02 | 2021 | |
| Csl Behring | $35.71 | 2025 | Haegarda |
| Merck Sharp & Dohme LLC | $31.33 | 2021-2023 | |
| Alk-Abello, INC | $28.69 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.50 | 2025 | Neffy |
| Sunovion Pharmaceuticals INC. | $28.17 | 2019 | |
| Greer Laboratories, INC. | $25.05 | 2025 | Oralair |
| Biocryst US Sales Co., LLC | $24.92 | 2024 | Orladeyo |
| Biofrontera INC. | $19.65 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.09 | 2023 | Arazlo, Jublia |
| Uswm, LLC | $19.00 | 2021 | |
| Leo Pharma INC. | $15.50 | 2024 | Adbry |
| Shire North American Group INC | $15.50 | 2019 | |
| Electromed, INC. | $15.16 | 2024 | Smartvest |
| Galderma Laboratories, L.P. | $14.88 | 2023 | Dysport |
| Biogen, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.